Search results
QRG Capital Management Inc. Sells 34,932 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)
ETF DAILY NEWS· 1 day agoQRG Capital Management Inc. cut its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 9.8% during the 4th quarter, ...
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss — Update
Morningstar· 6 days agoBy Kosaku Narioka Takeda Pharmaceutical reported a fourth-quarter loss and forecast a drop in annual net profit due partly to restructuring expenses. The ...
Takeda stock down 1% as operating profit declines
Investing.com· 6 days agoTakeda Pharmaceutical (TYO: 4502 ) Company Limited (NYSE: TAK ) has surpassed its management guidance for revenue and core earnings per share (EPS) in...
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
BioPharma Dive via Yahoo Finance· 2 days agoThe deal — worth $100 million up front and potentially billions more later on — gives Takeda an...
Takeda Pharmaceuticals earnings: profits, EPS down over 50% in Q4 financial results | Invezz
Invezz· 6 days agoThe company described it in a press release as “a year of significant loss-of-exclusivity impact”, a...
Scilex reaches settlement in patent lawsuit over Gloperba By Investing.com
Investing.com· 20 hours agoFederal Trade Commission and Department of Justice regarding its Settlement Agreement with Takeda ...
Catalyst's New CEO Has Big Ideas For The Small Biotech
Investor's Business Daily· 5 days agoBut after cutting his teeth at Big Pharma stalwarts, including Takeda Pharmaceutical and...
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Benzinga· 6 days agoOn Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited TAK announced a restructuring...
Improving the safety of iPS cell-derived pancreatic islets by eliminating unwanted cells
Medical Xpress· 2 days agoLtd., and Axcelead Drug Discovery Partners, Inc. The potential of iPS cells to become nearly any cell type in the body also creates concerns about possible risks of off-target cells...